We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
22 Oct 2020 - 25 Oct 2020
Virtual Venue
27 Oct 2020 - 31 Oct 2020
Virtual Venue
28 Oct 2020 - 30 Oct 2020
Virtual Venue

Cancer Cells Reprogram Immune Cells to Assist in Metastasis

By LabMedica International staff writers
Posted on 20 Jul 2020
Print article
Image: A blue tumor organoid surrounded by red NK cells (Photo courtesy of Isaac Chan, MD, PhD).
Image: A blue tumor organoid surrounded by red NK cells (Photo courtesy of Isaac Chan, MD, PhD).
Natural killer (NK) cells, a type of immune cell, are known to limit metastasis by inducing the death of cancer cells, but metastases still form in patients, so there must be ways for cancer cells to escape.

The loss of immunosurveillance is critical to breast cancer metastasis, immune checkpoint blockade has not been as effective in treating metastatic breast cancer as in melanoma or lung cancer. Breast cancer cells must overcome NK cell surveillance to form distant metastases, yet currently there is limited understanding of how metastatic cancer cells escape NK cell regulation.

Oncologists at the Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) and their colleagues used ex vivo and in vivo models of metastasis, to establish that keratin-14+ breast cancer cells are vulnerable to NK cells. They then discovered that exposure to cancer cells causes NK cells to lose their cytotoxic ability and promote metastatic outgrowth.

Gene expression comparisons revealed that healthy NK cells have an active NK cell molecular phenotype, whereas tumor-exposed (teNK) cells resemble resting NK cells. Receptor–ligand analysis between teNK cells and tumor cells revealed multiple potential targets. The team next showed that treatment with antibodies targeting T cell immunoreceptor with Ig and ITIM domains (TIGIT), antibodies targeting killer cell leptin-like receptor G1 (KLRG1), or small-molecule inhibitors of DNA methyltransferases (DMNT) each reduced colony formation. Combinations of DNMT inhibitors with anti-TIGIT or anti-KLRG1 antibodies further reduced metastatic potential.

Isaac Chan, MD, PhD, a Medical Oncologist and lead author of the study, said, “Metastatic disease is the main driver of breast cancer deaths, and we need a deeper understanding of how and why it occurs. Our study has identified a new strategy for cancer cells to co-opt the immune system. If we could prevent or reverse natural killer cell reprogramming in patients, it could be a new way to stop metastasis and reduce breast cancer mortality.”

The authors proposed that NK-directed therapies targeting these pathways would be effective in the adjuvant setting to prevent metastatic recurrence. The process may also apply to other cancer types. Immunotherapies that target NK cells could also potentially be used together with existing immunotherapies that stimulate T cells to fight cancer. The study was published on July 9, 2020 in the Journal of Cell Biology.

Related Links:
Johns Hopkins Kimmel Cancer Center


Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Ultrasound scan of fetus showing hydrops fetalis (Photo courtesy of Wikimedia Commons)

Exome Sequencing Identifies Genetic Loci Linked to the Fetal Syndrome Nonimmune Hydrops Fetalis

An exome sequencing technique was used to identify genetic loci linked to development of about 30% of cases of nonimmune hydrops fetalis (NIHF). Hydrops fetalis is a condition in the fetus characterized... Read more

Industry News

view channel
Illustration

2020 AACC Annual Scientific Meeting & Clinical Lab Expo to Be an All Virtual Event Due to Coronavirus Pandemic

The American Association for Clinical Chemistry (AACC Washington, DC, USA) has decided to hold the 2020 AACC Annual Scientific Meeting & Clinical Lab Expo as a virtual event, rather than as a live... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.